UEG Week 2023

The place of IL-23 blockers in crohn's disease

Benefit of JAKies in ulcerative colitis

Do different JAKies have different profiles?

New kids on the block - next generation therapeutics

Is IL-23 blockade breaking the ceiling in UC?

Anti-TL1A: on the way to precision medicine?

Update on JAKies

A lot of noise about IL-23 blockers - 1

Key topic S1P-modulation

Guselkumab readily controls symptoms in patients affected by UC: results from the QUASAR study

A lot of noise about IL-23 blockers - 2

Small molecules in IBD

News on IBD therapy!

S1P-Modulatoren im Fokus

Viel Wirbel um die Interleukin-23-Blockade

Rapido controllo dei sintomi nei pazienti affetti da RCU in trattamento con Guselkumab: risultati dallo studio QUASAR

Update zu JAK-Inhibitoren

Small molecules nelle IBD

Novità nelle terapie per le IBD!

Risankizumab vs. ustekinumab in CD: The SEQUENCE trial

First positive head-to-head trial in CD

Phase III results of filgotinib in CD

High IL23 expression at baseline is predictive of clinical remission and endoscopic response in CD patients treated with risankizumab

Head-to-head efficacy comparison of risankizumab vs ustekinumab in CD refractory to anti-TNF: results from the sequence trial

Long-term efficacy of obefazimod in UC

Ustekinumab vs. adamlimumab for prevention of early post-operative recurrence in CD

Mirikizumab reaches similar therapeutic outcomes in UC irrespective of prior exposure to advanced therapies.

Ustekinumab vs. adalimumab για την πρόληψη της πρώιμης μετεγχειρητικής ενδοσκοπικής υποτροπής της νόσου του Crohn

Mirikizumab resulta efficace in RCU a prescindere dalla precedente esposizione a terapie avanzate.

Comparazione testa a testa di Risankizumab e Ustekinumab in pazienti refrattari a terapia con anti-TNF: risultati dallo studio sequence

Elevati livelli basali di IL23 predicono la remissione clinica e la risposta endoscopica in pazienti affetti da MDC trattati con Risankizumab

Risankizumab in UC

Fast-acting etrasimod in UC

Mirikizumab in moderate to severe UC

Longterm endohistological response induced by mirikizumab in UC patients

Disease severity affects response in ozanimod treated pts.

Another p19 antibody in UC

Disease clearance induced by etrasimod and relationship between disease clearance and clinical outcome

PRA023 - a new anti-TL1A antibody in moderate to severe UC

Lange termijn efficaciteit van Obefazimod UC

Mirikizumab nella colite ulcerosa da moderata a grave

PRA023 - un nuovo anticorpo anti-TL1A nella colite ulcerosa da moderata a grave

Fase III resultaten met filgotinib in CD

How to prevent post-operative recurrence in CD?

Can we stop biologics?

S1P modulation: ozanimod vs. etrasimod

The quest for perfect predictors of response - AI entering the stage

Combined endpoints - composition and implementation in daily practice

Efficacy and safety of switching iv vs. sc

Navigating in the therapeutic IBD landscape

Infliximab sc application associated with better treatment persistence

More evidence that anti TNF-withdrawel increases relapse

To switch or not to switch in IBD - new real-life data already available

Navigeren in het therapeutisch landschap in IBD

Infliximab sc führt zu besseren Langzeitergebnissen

Konwersja do terapii podskórnej NZJ - nowe dane typu real-life

SEQUENCE study

Surgical news: prevention of post-operative recurrence in crohn's disease

Did GETAID close the window of opportunity?

Medical news: Which treatment and when?

Stopping adalimumab in early CD?

Postoperative recurrence in Crohn's disease after ileocecal resection - the PORCSE study

Nawroty pooperacyjne u pacjentów z chorobą Leśniowskiego-Crohna po resekcji ileocekalnej - badanie PORCSE

Actualités médicales: Quel traitement et quand?

SEQUENCE Studie

Peut-on arrêter l'adalimumab dans la maladie de Crohn précoce?

Hat GETAID das "Window of opportunity" geschlossen?

Nouveauté sur la chirurgie: Prévention de la récidive post-opératoire dans la maladie de Crohn

The anti TL1A/Dx-toolbox package: Are we entering precision medicine?

Which maintenance therapy in AS-CU is responding to steroids?

Quel traitement d'entretien dans l'AS-CU répondant aux stéroïdes?

Anti-TL1A im Paket mit der Dx-Toolbox - Einstieg in die Präzisionsmedizin?

Comprehensive disease control - a new currency

Comprehensive disease control - eine neue Währung

New safety signals on JAKies?

S1P modulation: effective and safe?

What do we know about multi-failures?

Effective control of EIMs in CD patients treated with risankizumab

Is risankinumab effective for EIMs of IBD?

Do JAK inhibitors cause acne?

Is it feasible to stop effective anti-TNF therapy in IBD? The GETECCU RCT

Czy możemy bezpiecznie przerwać skuteczną terapię anty-TNF w NZJ - wyniki badania grupy GETECCU

Προκαλούν οι αναστολείς των JAK ακμή;

Είναι το risankisumab αποτελεσματικό για τη θεραπεία των εξωεντερικών εκδηλώσεων των ΙΦΝΕ;

Efficace controllo delle MEI in pazienti affetti da MDC trattati con Risankizumab

Neutrophil fibroblast crosstalk is driving fribrosis in CD

Morphologic alteration of mesentric lymph nodes under ozanimod

Neutrophile Fibroblasteninteraktion treibt die Fibrose bei Morbus Crohn

Morphologische Veränderung mesenterialer Lymphknoten unter Ozanimod